Zuranolone is a two-week, once-daily oral drug under investigation for the treatment of MDD and postpartum depression designed to potentially provide a rapid-acting, sustainable treatment option.
It is an investigational, oral, neuroactive steroid GABA-A receptor positive allosteric modulator.
